6C
6C1.F CytomX Therapeutics Inc
- Market cap
- EUR 397M
- P/E
- -
- P/B
- 1.48x
- ROE
- -27.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 6C1.F undervalued?
Graham numberThe Graham number of CytomX Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CytomX Therapeutics Inc fundamental analysis
No fundamental analysis for CytomX Therapeutics Inc yet.
CytomX Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index fo…
Full company profileCytomX Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CytomX Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 15.0M | 71.6M | 59.5M | 57.5M | 100M | 69.6M | 53.2M | 101M | 138M | 76.2M | 17.8M |
| Operating Income | -59.6M | -46.3M | -77.9M | -111M | -48.6M | -83.8M | -101M | -6.48M | 25.0M | -22.4M | -89.3M |
| EBITDA | - | -44.6M | -76.0M | -100M | -46.0M | -81.1M | -98.9M | -4.31M | 26.8M | -21.0M | -88.3M |
| Net Income | -58.9M | -43.1M | -84.6M | -102M | -32.9M | -83.6M | -99.3M | -569K | 31.9M | -17.4M | -78.5M |
| EPS | - | -1.12 | -1.88 | -2.25 | -0.68 | -1.28 | -1.50 | -0.01 | 0.41 | -0.10 | -0.36 |
| Balance Sheet | |||||||||||
| Total Assets | 199M | 398M | 457M | 341M | 359M | 339M | 261M | 202M | 121M | 152M | 365M |
| Total Liabilities | 121M | 328M | 326M | 290M | 309M | 250M | 347M | 249M | 121M | 52.6M | 79.8M |
| Shareholders' Equity | 78.5M | 69.9M | 131M | 51.1M | 49.8M | 89.4M | -85.8M | -47.4M | -456K | 99.0M | 285M |
| Cash & Short-term Investments | 105M | 178M | 248M | 188M | 192M | 206M | 194M | 17.2M | 38.1M | 12.7M | 34.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.03M | 170M | -75.5M | -140M | 5.26M | -119M | -111M | -56.0M | -86.2M | -75.6M | -36.0M |
| Capital Expenditure | 2.18M | 1.56M | 3.79M | 3.50M | 2.31M | 1.61M | 1.74M | 840K | 310K | 220K | 0.00 |
| Free Cash Flow | - | 169M | -79.3M | -144M | 2.95M | -121M | -113M | -56.9M | -86.5M | -75.8M | -36.7M |
| Ratios | |||||||||||
| ROE | -75.1% | -61.7% | -64.6% | -200.0% | -66.0% | -93.5% | - | - | - | -17.5% | -27.6% |
| ROA | -29.6% | -10.8% | -18.5% | -30.0% | -9.2% | -24.6% | -38.1% | -0.3% | 26.4% | -11.5% | -21.5% |
| Net Profit Margin | -391.5% | -60.2% | -142.2% | -177.8% | -32.8% | -120.2% | -186.8% | -0.6% | 23.1% | -22.8% | -440.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
CytomX Therapeutics Inc dividends
CytomX Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Who owns CytomX Therapeutics Inc
- Insiders 0.57%
- Institutions 99.43%
- Public & others 0.00%
- Shares outstanding 218M
- Free float 180M
CytomX Therapeutics Inc company profile
- Company name
- CytomX Therapeutics Inc
- Ticker
- 6C1.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 69
- Fiscal year end
- December
- Address
- 151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
- Phone
- 650 515 3185
- Website
- cytomx.com
About CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
CytomX Therapeutics Inc management
10- Dr. Sean A. McCarthy DPHILChairman & CEO · born 1967
- Mr. Christopher W. OgdenSVP, CFO & Secretary · born 1984
- Ms. Rachael LesterChief Business Officer & Senior VP · born 1978
- Dr. Marcia P. Belvin Ph.D.Senior VP & Chief Scientific Officer · born 1967
- Ms. Alejandra Veronica Carvajal J.D.Chief Legal Officer · born 1974
- Ms. Danielle Olander-MoghadassianSenior VP & Chief Human Resources Officer
- Ms. Leslie Robbins J.D.Senior Vice President of Intellectual Property
- Dr. Yu-Waye Chu M.D.Senior VP & Chief Medical Officer · born 1968
- Ms. Dawn BensonSenior Vice President of Quality & Product Manufacturing
- Dr. Stephanie Robertson Ph.D.Senior Vice President of Alliances & Program Leadership